Jiangsu Simcere Pharmaceutical R&D Co. Ltd. has disclosed alkyne compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described pyrrolopyrimidine derivatives as Wee1-like protein kinase (Wee-1) inhibitors reported to be useful for the treatment of cancer.

Shanghai Xucheng Pharmatech Co. Ltd. has divulged retinoid acid receptor γ (RARγ) agonists reported to be useful for the treatment of acne, psoriasis, ichthyosis, keratosis, skin hyperpigmentation and dry eye.

Sichuan Haisco Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently bonded to an EGFR (HER1; erbB1) targeting moiety through a linker reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).

Viva Star Biosciences Ltd. has synthesized lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of fibrosis, chronic kidney disease, diabetic nephropathy, nonalcoholic steatohepatitis (NASH), systemic scleroderma (systemic sclerosis) and idiopathic pulmonary fibrosis.

Sitryx Therapeutics Ltd. has disclosed 2-methylene-4-oxo-butanoic acid derivative compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) activators reported to be useful for the treatment of inflammatory disorders.

Xuanzhu Pharma Co. Ltd. has described tricyclic ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Genfleet Therapeutics (Shanghai) Inc. has divulged pyridino- or pyrimido-cyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

The Dana-Farber Cancer Institute has identified molecular glue degraders comprising a cereblon (CRBN) ubiquitin ligase-binding moiety covalently bound to a zinc finger protein Helios (IKZF2) ligand reported to be useful for the treatment of cancer. 

Scinnohub Pharmaceutical Co. Ltd. has synthesized S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.